E-TABM-43 - Transcription profiling of advanced human breast cancers treated with a dose-intense epirubicin /cyclophosphamide regimen followed by mastectomy
Submitted on 20 September 2005, released on 26 March 2007, last updated on 10 October 2013
A "Cartes d'Identite des Tumeurs" (CIT) project from the french Ligue Nationale Contre le Cancer (http://cit.ligue-cancer.net). 37 samples hybridized on Affymetrix HG-U133A arrays. Analysis of advanced breast cancers treated with a dose-intense epirubicin /cyclophosphamide regimen followed by mastectomy; Validation of TP53-related genes in breast and bladder cancers. We found that a complete response to chemotherapy was only observed in TP53 mutant tumours. We further show that, among TP53 mutant tumours, high basalcytokeratin and low ESR1 expression levels were associated with complete responses. These observations pave the way to molecular tailoring of chemotherapy in breast cancer.
transcription profiling by array, clinical history, disease state
Fabien Petel <PetelF@ligue-cancer.net>, Anne de Roquancourt, Anne Janin, Aurélien de Reyniès, David Rickman, Elisabeth Turpin, Francis Duboscq, Hany Soliman, Hugues de Thé, Jacqueline Lehman, Jean-Louis Misset, Jean-Paul Feugeas, Louis-François Plassa, Marc Espié, Mariana Varna, Michel Marty, Olivier Cussenot, Philippe Bertheau, Pierre Mongiat-Artus, Yves Beuzard
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. PLoS Med 4(3):e90 (2007), Europe PMC 17388661